Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database
Parikh, Kaushal, Dimou, Anastasios, Leventakos, Konstantinos, Mansfield, Aaron S., Shanshal, Mohamed, Wan, Yin, Lin, Huamao M., Vincent, Sylvie, Elliott, Jennifer, Bonta, Ioana R.
Published in Journal of thoracic oncology (15.07.2024)
Published in Journal of thoracic oncology (15.07.2024)
Get full text
Journal Article
Impact of EML4-ALK fusion variant and co-occurring TP53 mutation on treatment duration of first-line next-generation ALK TKIs in ALK fusion+ NSCLC
Parikh, Kaushal, Dimou, Anastasios, Leventakos, Konstantinos, Wan, Yin, Lin, Huamao Mark, Vincent, Sylvie, Elliott, Jennifer, Bonta, Ioana R
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article